by Wiley edited by Sadie Harley, reviewed by Robert Egan Editors’ notes The GIST Add as preferred source Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0 Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as high in men […]
by Washington University in St. Louis edited by Sadie Harley, reviewed by Robert Egan Editors’ notes The GIST Add as preferred source Researchers at WashU Medicine and their collaborators have created an immune cell atlas of multiple myeloma, a cancer of the bone marrow. The new resource could improve prognosis and guide development of new immunotherapies. Shown is
Inflammatory immune cells predict survival and relapse in multiple myeloma Read More »
by American Society of Hematology edited by Sadie Harley, reviewed by Andrew Zinin Editors’ notes Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0 Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more
Analysis shows CAR T immune-related adverse events are related to higher non-cancer mortality Reports and Proceedings University of Pennsylvania School of Medicine ORLANDO – Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, are associated with high rates of death
by Lori Solomon edited by Stephanie Baum, reviewed by Robert Egan Editors’ notes The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM). Darzalex Faspro is now the first and only approved treatment for HR-SMM. The approval is based on results
FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma Read More »
by Lori Solomon edited by Gaby Clark, reviewed by Andrew Zinin Editors’ notes The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma. The approval is for patients who have received at least two prior lines of therapy, including
FDA approves Blenrep for relapsed or refractory multiple myeloma Read More »
by Sylvester Comprehensive Cancer Center edited by Lisa Lock, reviewed by Robert Egan Molecular time and temporal relationship between large chromosomal gains in multiple myeloma. Credit: Nature Genetics (2025). DOI: 10.1038/s41588-025-02292-1 A new study focused on multiple myeloma, the second most common blood cancer, may lead to better ways to group patients by the state of their DNA and define
New study maps out the timeline of DNA damage for multiple myeloma Read More »
Dana-Farber Cancer Institute Boston, MA — Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions. The new method, known as SWIFT-seq, utilizes single-cell sequencing to profile circulating tumor cells (CTCs) in the blood, offering a non-invasive alternative to traditional bone marrow
Dana-Farber Cancer Institute unveils groundbreaking blood test for multiple myeloma Read More »
Vitae, vulputate lorem id egestas neque egestas habitant sit ante nec.
✆ Phone (appointments): 714-639-4013
Email: care@imedmg.com
Address: 615 E Chapman Ave, Suite #300, Orange, CA 92866